Literature DB >> 29946778

Non-Hodgkin Lymphoma Metabolism.

Brian James Kirsch1,2, Shu-Jyuan Chang3, Anne Le4.   

Abstract

KEY POINTS: Non-Hodgkin lymphomas (NHLs) are a heterogeneous group of lymphoid neoplasms with differing biological characteristics. About 90% of all lymphomas in the United States originate from B lymphocytes, while the remaining originate from T cells [1]. The treatment of NHLs depends on neoplastic histology and the stage of the tumor, which will indicate whether radiotherapy, chemotherapy, or a combination is the best suitable treatment [2]. The American Cancer Society describes the staging of lymphoma as follows: Stage I is lymphoma in a single node or area. Stage II is when that lymphoma has spread to another node or organ tissue. Stage III is when it has spread to lymph nodes in two sides of the diaphragm. Stage IV is when the cancer has significantly spread to organs outside the lymph system. Radiation therapy is the traditional therapeutic route for localized follicular and mucosa-associated lymphomas. Chemotherapy is utilized for the treatment of large cell lymphomas and high-grade lymphomas [2]. However, treatment of indolent lymphomas remains problematic as the patients often have metastasis for which no standard approach exists [2].

Entities:  

Keywords:  Aerobic glycolysis; Fatty acid metabolism; Gene expression; Glutamine metabolism; Heterogeneous malignant lymphomas; Lactic acidosis; mTOR signaling

Mesh:

Year:  2018        PMID: 29946778     DOI: 10.1007/978-3-319-77736-8_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  55 in total

1.  Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming.

Authors:  Clifford D L Folmes; Timothy J Nelson; Almudena Martinez-Fernandez; D Kent Arrell; Jelena Zlatkovic Lindor; Petras P Dzeja; Yasuhiro Ikeda; Carmen Perez-Terzic; Andre Terzic
Journal:  Cell Metab       Date:  2011-08-03       Impact factor: 27.287

Review 2.  B-cell receptor signaling in diffuse large B-cell lymphoma.

Authors:  Ryan M Young; Arthur L Shaffer; James D Phelan; Louis M Staudt
Journal:  Semin Hematol       Date:  2015-01-15       Impact factor: 3.851

3.  Dysregulation of fatty acid synthesis and glycolysis in non-Hodgkin lymphoma.

Authors:  Aadra P Bhatt; Sarah R Jacobs; Alex J Freemerman; Liza Makowski; Jeffrey C Rathmell; Dirk P Dittmer; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-29       Impact factor: 11.205

4.  Rapamycin is efficacious against primary effusion lymphoma (PEL) cell lines in vivo by inhibiting autocrine signaling.

Authors:  Sang-Hoon Sin; Debasmita Roy; Ling Wang; Michelle R Staudt; Farnaz D Fakhari; Dhavalkumar D Patel; David Henry; William J Harrington; Blossom A Damania; Dirk P Dittmer
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

5.  Blocking lactate export by inhibiting the Myc target MCT1 Disables glycolysis and glutathione synthesis.

Authors:  Joanne R Doherty; Chunying Yang; Kristen E N Scott; Michael D Cameron; Mohammad Fallahi; Weimin Li; Mark A Hall; Antonio L Amelio; Jitendra K Mishra; Fangzheng Li; Mariola Tortosa; Heide Marika Genau; Robert J Rounbehler; Yunqi Lu; Chi V Dang; K Ganesh Kumar; Andrew A Butler; Thomas D Bannister; Andrea T Hooper; Keziban Unsal-Kacmaz; William R Roush; John L Cleveland
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

Review 6.  MYC, Metabolism, and Cancer.

Authors:  Zachary E Stine; Zandra E Walton; Brian J Altman; Annie L Hsieh; Chi V Dang
Journal:  Cancer Discov       Date:  2015-09-17       Impact factor: 39.397

7.  Serum LDH concentration in non-Hodgkin's lymphomas. Relationship to histologic type, tumor mass, and presentation features.

Authors:  G Fasola; R Fanin; F Gherlinzoni; P Galieni; D Taruscio; G Frezza; P Mazza; S Pileri; M Baccarani
Journal:  Acta Haematol       Date:  1984       Impact factor: 2.195

Review 8.  Rethinking the Warburg effect with Myc micromanaging glutamine metabolism.

Authors:  Chi V Dang
Journal:  Cancer Res       Date:  2010-01-19       Impact factor: 12.701

9.  Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma.

Authors:  Pilar Caro; Amar U Kishan; Erik Norberg; Illana A Stanley; Bjoern Chapuy; Scott B Ficarro; Klaudia Polak; Daniel Tondera; John Gounarides; Hong Yin; Feng Zhou; Michael R Green; Linfeng Chen; Stefano Monti; Jarrod A Marto; Margaret A Shipp; Nika N Danial
Journal:  Cancer Cell       Date:  2012-10-16       Impact factor: 31.743

10.  Reversal of the glycolytic phenotype of primary effusion lymphoma cells by combined targeting of cellular metabolism and PI3K/Akt/ mTOR signaling.

Authors:  Laura Mediani; Federica Gibellini; Jessika Bertacchini; Chiara Frasson; Raffaella Bosco; Benedetta Accordi; Giuseppe Basso; Massimo Bonora; Maria Luisa Calabrò; Adriana Mattiolo; Gianluca Sgarbi; Alessandra Baracca; Paolo Pinton; Giovanni Riva; Enrico Rampazzo; Luca Petrizza; Luca Prodi; Daniela Milani; Mario Luppi; Leonardo Potenza; Anto De Pol; Lucio Cocco; Silvano Capitani; Sandra Marmiroli
Journal:  Oncotarget       Date:  2016-02-02
View more
  2 in total

1.  Rituximab combined with GDP regimen can effectively improve the efficacy and immune function of non-Hodgkin lymphoma.

Authors:  Chao Song; Yanli Feng; Fanmei Ge; Zhiyun Zhang; Baoxiong Su
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

Review 2.  The Metabolic Interplay between Cancer and Other Diseases.

Authors:  Anne Le; Sunag Udupa; Cissy Zhang
Journal:  Trends Cancer       Date:  2019-11-21
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.